TransCode Therapeutics Announces Pre-Clinical Glioblastoma Results With Lead Therapeutic Candidate, TTX-MC138
Portfolio Pulse from Benzinga Newsdesk
TransCode Therapeutics, Inc. (NASDAQ:RNAZ) announced positive pre-clinical results for its lead therapeutic candidate, TTX-MC138, in treating glioblastoma multiforme (GBM) tumors. The candidate was delivered to brain tumors and effectively engaged its target. TTX-MC138 consists of an iron oxide nanocarrier conjugated to a nucleic acid designed to inhibit the oncogenic RNA, microRNA-10b. The company's first-in-human clinical trial with TTX-MC138 is open for enrollment and has dosed its first patient.
September 25, 2023 | 12:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
TransCode Therapeutics announced positive pre-clinical results for its lead therapeutic candidate, TTX-MC138, in treating GBM tumors. The company's first clinical trial with TTX-MC138 is now open for enrollment.
The positive pre-clinical results for TTX-MC138, a therapeutic candidate for treating GBM tumors, is a significant milestone for TransCode Therapeutics. This could potentially lead to an increase in the company's stock price in the short term as it indicates progress in their product development. The opening of the first clinical trial for TTX-MC138 also adds to the positive news as it moves the product closer to potential commercialization.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100